Gene Set Index Based on Different Modules May Help Differentiate the Mechanisms of Alzheimer’s Disease and Vascular Dementia

References

• Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719–732. doi:10.1016/j.jalz.2016.02.01027179961
   PubMed Web of Science ®Google Scholar
• Zou D, Li R, Huang X, et al. Identification of molecular correlations of RBM8A with autophagy in Alzheimer’s disease. Aging. 2019;11(23):11673–11685. doi:10.18632/aging.10257131816601
   PubMedGoogle Scholar
• Bose S, Cho J. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch Pharm Res. 2013;36(9):1039–1050. doi:10.1007/s12272-013-0161-z23771498
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–356. doi:10.1126/science.107299412130773
   PubMed Web of Science ®Google Scholar
• Jian C, Lu M, Zhang Z, et al. miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP. Life Sci. 2017;182:104–111.28533191
   PubMed Web of Science ®Google Scholar
• Zhu JB, Tan CC, Tan L, Yu JT. State of Play in Alzheimer’s Disease Genetics. J Alzheimers Dis. 2017;58(3):631–659.28505974
   PubMed Web of Science ®Google Scholar
• Zou C, Wang J, Huang X, Jian C, Zou D, Li X. Analysis of transcription factor- and ncRNA-mediated potential pathogenic gene modules in Alzheimer’s disease. Aging. 2019;11(16):6109–6119.31422384
   PubMedGoogle Scholar
• Zou D, Liu C, Zhang Q, et al. Association between polymorphisms in microRNAs and ischemic stroke in an Asian population: evidence based on 6083 cases and 7248 controls. Clin Interv Aging. 2018;13:1709–1726.30254431
   PubMed Web of Science ®Google Scholar
• Zekry D, Duyckaerts C, Hauw JJ. Démences vasculaires et démences mixtesVascular dementia and mixed dementia. [Vascular dementia and mixed dementia]. Presse Med. 2007;36(10 Pt 2):1469–1476. French.17553655
   PubMed Web of Science ®Google Scholar
• Bennett D. Public health importance of vascular dementia and Alzheimer’s disease with cerebrovascular disease. Int J Clin Pract Suppl. 2001;1(120):41–48.
   Google Scholar
• Roman G. Diagnosis of vascular dementia and Alzheimer’s disease. Int J Clin Pract Suppl. 2001;1(120):9–13.
   Google Scholar
• Otsuka M, Yamaguchi K, Ueki A. Similarities and differences between Alzheimer’s disease and vascular dementia from the viewpoint of nutrition. Ann N Y Acad Sci. 2002;977(1):155–161. doi:10.1111/j.1749-6632.2002.tb04811.x12480746
   PubMed Web of Science ®Google Scholar
• Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555–563. doi:10.1016/j.bbr.2010.11.05821145918
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.25792098
   PubMed Web of Science ®Google Scholar
• Kauwe JS, Bailey MH, Ridge PG, et al. Genome-wide association study of CSF levels of 59 Alzheimer’s disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet. 2014;10(10):e1004758. doi:10.1371/journal.pgen.100475825340798
   PubMed Web of Science ®Google Scholar
• Semple BD, Kossmann T, Morganti-Kossmann MC. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab. 2010;30(3):459–473. doi:10.1038/jcbfm.2009.24019904283
   PubMed Web of Science ®Google Scholar
• Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. Brain Pathol. 2009;19(3):392–398. doi:10.1111/j.1750-3639.2008.00188.x18637012
   PubMed Web of Science ®Google Scholar
• Old EA, Malcangio M. Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. Curr Opin Pharmacol. 2012;12(1):67–73. doi:10.1016/j.coph.2011.10.01522056024
   PubMed Web of Science ®Google Scholar
• Hartlage-Rubsamen M, Waniek A, Meissner J, et al. Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease. Acta Neuropathol. 2015;129(4):565–583. doi:10.1007/s00401-015-1395-225666182
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis. 2010;19(1):355–361. doi:10.3233/JAD-2010-121920061650
   PubMed Web of Science ®Google Scholar
• Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One. 2012;7(1):e30525. doi:10.1371/journal.pone.003052522303443
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv00725605792
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.011822455463
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273. doi:10.1038/ng118012808457
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.00426771021
   PubMed Web of Science ®Google Scholar
• Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–D386. doi:10.1093/nar/gkx101329087512
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.123930314597658
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D368. doi:10.1093/nar/gkw93727924014
   PubMed Web of Science ®Google Scholar
• Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res. 2010;38(WebServer issue):W445–449. doi:10.1093/nar/gkq31120444869
   PubMed Web of Science ®Google Scholar
• Mooers BHM. Shortcuts for faster image creation in PyMOL. Protein Sci. 2020;29(1):268–276. doi:10.1002/pro.378131710740
   PubMed Web of Science ®Google Scholar
• Lopez-Sanz D, Bruna R, Delgado-Losada ML, et al. Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia. Alzheimers Res Ther. 2019;11(1):49. doi:10.1186/s13195-019-0502-331151467
   PubMed Web of Science ®Google Scholar
• Serra A, Onlu S, Coretto P, Greco D. An integrated quantitative structure and mechanism of action-activity relationship model of human serum albumin binding. J Cheminform. 2019;11(1):38. doi:10.1186/s13321-019-0359-231172382
   PubMed Web of Science ®Google Scholar
• Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12(1):77. doi:10.1186/1471-2105-12-77
   PubMed Web of Science ®Google Scholar
• Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer’s disease: evidence from genome-wide pathway analysis. J Alzheimers Dis. 2010;20(4):1107–1118. doi:10.3233/JAD-2010-10001820413860
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13(11):460–469. doi:10.1016/j.molmed.2007.09.00218029230
   PubMed Web of Science ®Google Scholar
• Chami B, Steel AJ, De La Monte SM, Sutherland GT. The rise and fall of insulin signaling in Alzheimer’s disease. Metab Brain Dis. 2016;31(3):497–515.26883429
   PubMed Web of Science ®Google Scholar
• Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci. 2011;121(9):367–387. doi:10.1042/CS20110164
   PubMed Web of Science ®Google Scholar
• Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology. 2010;58(3):561–568. doi:10.1016/j.neuropharm.2009.11.01019951717
   PubMed Web of Science ®Google Scholar
• Ogunshola OO, Antoniou X. Contribution of hypoxia to Alzheimer’s disease: is HIF-1α a mediator of neurodegeneration? Cell Mol Life Sci. 2009;66(22):3555–3563. doi:10.1007/s00018-009-0141-019763399
   PubMed Web of Science ®Google Scholar
• Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-kappaB for treatment of Alzheimer’s disease. Pharmacol Res. 2018;129:262–273.29179999
   PubMed Web of Science ®Google Scholar
• Rahman MR, Islam T, Zaman T, et al. Identification of molecular signatures and pathways to identify novel therapeutic targets in Alzheimer’s disease: insights from a systems biomedicine perspective. Genomics. 2020;112(2):1290–1299.31377428
   PubMed Web of Science ®Google Scholar
• Rahman MR, Islam T, Turanli B, et al. Network-based approach to identify molecular signatures and therapeutic agents in Alzheimer’s disease. Comput Biol Chem. 2019;78:431–439.30606694
   PubMed Web of Science ®Google Scholar
• Rahman MR, Islam T, Shahjaman M, et al. Discovering Biomarkers and Pathways Shared by Alzheimer’s Disease and Ischemic Stroke to Identify Novel Therapeutic Targets. Medicina. 2019;55:5.
   Web of Science ®Google Scholar
• Hong MG, Alexeyenko A, Lambert JC, Amouyel P, Prince JA. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J Hum Genet. 2010;55(10):707–709.20668461
   PubMed Web of Science ®Google Scholar
• Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One. 2010;5(11):e13950.21085570
   PubMed Web of Science ®Google Scholar
• Liu G, Jiang Y, Wang P, et al. Cell adhesion molecules contribute to Alzheimer’s disease: multiple pathway analyses of two genome-wide association studies. J Neurochem. 2012;120(1):190–198.22017384
   PubMed Web of Science ®Google Scholar
• Xiang Z, Xu M, Liao M, et al. Integrating Genome-Wide Association Study and Brain Expression Data Highlights Cell Adhesion Molecules and Purine Metabolism in Alzheimer’s Disease. Mol Neurobiol. 2015;52(1):514–521.25204495
   PubMed Web of Science ®Google Scholar
• Bernardi F, Lanzone A, Cento RM, et al. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer’s disease and vascular dementia. Eur J Endocrinol. 2000;142(5):466–471.10802523
   PubMed Web of Science ®Google Scholar